News >

Novel Strategies Emerging to Tackle Heterogeneity of TNBC

Caroline Seymour
Published: Monday, Jul 08, 2019

Kari B. Wisinski, MD

Kari B. Wisinski, MD

Metastatic triple-negative breast cancer (TNBC) is a disease in which treatment was once heavily rooted in chemotherapy. Now, with the emergence of novel agents, clinicians are learning how to treat the heterogeneity of the disease appropriately, explained Kari B. Wisinski, MD, in a presentation during the 2019 OncLive® State of the Science Summit on Breast Cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x